The Role of Biologic Therapy in Severe Asthma: A Shifting Treatment Paradigm

The Role of Biologic Therapy in Severe Asthma: A Shifting Treatment Paradigm is organized by National Association for Continuing Education (NACE).

Start Date: 06/01/2019
Expiration Date: 05/31/2020

Target Audience: 
Pulmonologists, Primary Care Physicians, Nurse Practitioners, Physician Assistants

Credits:
• 1.0 AMA PRA Category 1 Credit™
• 1.0 AANP Contact hour which includes 0.75 pharmacology hours

Summary:
Asthma is a heterogenous disorder usually characterized by chronic airway inflammation, and defined by respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation. The disorder that affects 18.7 million adults and 7 million children in the United States. This activity will examine the current concepts in the pathophysiology of asthma and type 2 inflammation, discuss the clinical assessment of asthma control and risk factors for poor asthma outcomes, how to individualize treatment and recognize appropriate candidates for biologicals, and the impact of comorbid conditions.

This webcast was recorded live at the Conversations in Pulmonology 2019 Live Virtual Broadcast and is being used with the permission of the presenters.

Learning Objectives:
After completing this program participants should be able to:
• Describe the current concepts in the pathophysiology of asthma and type 2 inflammation, and the implications of biologic therapies in the era of precision medicine
• Discuss the clinical assessment of asthma control and risk factors for poor asthma outcomes
• Individualize the treatment approach for patients with moderate to severe asthma while recognizing appropriate candidates for biologicals and other advanced therapies
• Recognize the impact of comorbid conditions on asthma control and evidence-based approaches to their treatment

Additional details will be posted as soon as information is available.